Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease
- PMID: 29133763
- PMCID: PMC5695060
- DOI: 10.4103/0366-6999.218025
Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease
Abstract
Background: Damage of the medial prefrontal cortex (mPFC) results in similar characteristics to the cognitive deficiency seen with the progress of Parkinson's disease (PD). Since the course of mPFC damage is still unclear, our study aimed to investigate the effects of melatonin (MT) on neurotoxicity in the mPFC of a rat model of PD.
Methods: One hundred and fifty-four normal, male Wistar rats were randomly divided into the following five groups: normal + normal saline (NS), normal + 6-hydroxydopamine (6-OHDA), sham pinealectomy (PX) + 6-OHDA, PX + 6-OHDA, and MT + 6-OHDA. 6-OHDA was injected into the right substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) of each group, except normal + NS, 60 days after the PX. In the MT treatment group, MT was administered immediately after the intraperitoneal injection at 4 p.m. every day, for 14 days. Neuronal apoptosis in the mPFC was examined using the TUNEL method, while the expression of tyrosine hydroxylase (TH), Bax,and Bcl-2 in this region was measured using immunohistochemistry. The concentration of malondialdehyde (MDA) in the mPFC was examined using the thiobarbituric acid method.
Results: Rats in the normal + 6-OHDA and sham PX + 6-OHDA groups were combined into one group (Group N + 6-OHDA) since there was no significant discrepancy between the groups for all the detected parameters. Apoptosis of cells in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups was successively significantly increased (Hc = 256.25, P < 0.001). The gray value of TH (+) fibers in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups was also successively significantly increased (F = 99.33, P < 0.001). The staining intensities of Bax and Bcl-2 were as follows: Group NS +/+, Group MT + 6-OHDA ++/+, Group N + 6-OHDA ++/+, and PX + 6-OHDA +++/+. The concentrations of MDA in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups were significantly increased in sequence (Hc = 296.309, P < 0.001).
Conclusions: Neuronal damage of the VTA by 6-OHDA might induce VTA-mPFC nerve fibers to undergo anterograde nerve damage, in turn inducing transneuronal damage of the mPFC. PX significantly exacerbated the neurotoxicity in the mPFC, which was induced by the neuronal injury of the VTA. However, MT replacement therapy significantly alleviated the neurotoxicity in the mPFC.
Conflict of interest statement
There are no conflicts of interest.
Figures


Similar articles
-
Effects of Pinealectomy and Gonadectomy on Olfactory Bulb Dopaminergic Neurons in Rats.Chin Med J (Engl). 2017 Oct 5;130(19):2302-2306. doi: 10.4103/0366-6999.215336. Chin Med J (Engl). 2017. PMID: 28937035 Free PMC article.
-
Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model.Free Radic Res. 2015;49(8):1004-14. doi: 10.3109/10715762.2015.1027198. Epub 2015 Apr 25. Free Radic Res. 2015. PMID: 25791066
-
[Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].Zhongguo Zhong Yao Za Zhi. 2014 May;39(9):1660-5. Zhongguo Zhong Yao Za Zhi. 2014. PMID: 25095380 Chinese.
-
Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.Neurochem Int. 2014 Dec;79:1-11. doi: 10.1016/j.neuint.2014.09.005. Epub 2014 Sep 28. Neurochem Int. 2014. PMID: 25263280
-
Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions.Stereotact Funct Neurosurg. 2000;75(2-3):66-75. doi: 10.1159/000048385. Stereotact Funct Neurosurg. 2000. PMID: 11740172
Cited by
-
Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation.Oxid Med Cell Longev. 2020 Oct 12;2020:2360872. doi: 10.1155/2020/2360872. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 33101584 Free PMC article. Review.
-
Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease.Front Pharmacol. 2021 Apr 15;12:650597. doi: 10.3389/fphar.2021.650597. eCollection 2021. Front Pharmacol. 2021. PMID: 33935759 Free PMC article. Review.
-
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents.Antioxidants (Basel). 2021 Oct 9;10(10):1584. doi: 10.3390/antiox10101584. Antioxidants (Basel). 2021. PMID: 34679721 Free PMC article.
-
The Effect of Melatonin Modulation of Non-coding RNAs on Central Nervous System Disorders: An Updated Review.Curr Neuropharmacol. 2021;19(1):3-23. doi: 10.2174/1570159X18666200503024700. Curr Neuropharmacol. 2021. PMID: 32359338 Free PMC article. Review.
-
Melatonin: Clinical Perspectives in Neurodegeneration.Front Endocrinol (Lausanne). 2019 Jul 16;10:480. doi: 10.3389/fendo.2019.00480. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31379746 Free PMC article. Review.
References
-
- Sgambato-Faure V, Buggia V, Gilbert F, Lévesque D, Benabid AL, Berger F, et al. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol. 2005;64:936–47. doi: 10.1097/01.jnen.0000186922.42592.b7. - PubMed
-
- Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review. J Neuropsychiatry Clin Neurosci. 1997;9:222–30. doi: 10.1176/jnp.9.2.222. - PubMed
-
- Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25:704–9. doi: 10.1002/mds.22868. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous